期刊
ADVANCES IN THERAPY
卷 38, 期 8, 页码 4195-4214出版社
SPRINGER
DOI: 10.1007/s12325-021-01791-x
关键词
Obstructive sleep apnoea; SGLT-2i; Diabetes mellitus; Renal function; Vascular disease; Rehabilitation
This review examines the relationship between obstructive sleep apnoea (OSA) and type 2 diabetes mellitus (T2DM), suggesting the potential use of sodium-glucose co-transporter-2 inhibitors (SGLT-2i) as a treatment target. It also proposes that SGLT-2i indications could expand beyond current ones, including glucose, lipids, uric acid, blood pressure, and body weight control, as well as chronic heart failure and kidney disease prevention.
Obstructive sleep apnoea (OSA) is characterized by frequent apnoea episodes during sleep due to upper airway obstruction. The present review summarizes current knowledge on inter-relationships between OSA and type 2 diabetes mellitus (T2DM) and suggests the former as a possible target for sodium-glucose co-transporter-2 inhibitors (SGLT-2i). Based on pathophysiological mechanisms underlying OSA onset and renal SGLT-2 effects, we suggest that SGLT-2i indications might expand beyond current ones, including glucose, lipids, uric acid, blood pressure, and body weight control as well as chronic heart failure and kidney disease prevention.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据